Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
Rhea-AI Summary
Valion Bio (Nasdaq: VBIO) announced that subsidiary Velocity Bioworks secured an exclusive commercial development and license agreement for LarmorBio's BioScan-NMR™ platform, a next-generation NMR system.
The first commercial installation is targeted for July 2026 in San Antonio, positioning Velocity Bioworks as a reference site for advanced NMR-based diagnostics.
Positive
- Exclusive commercial development and license rights to LarmorBio's BioScan-NMR™ platform
- First commercial BioScan-NMR installation targeted for July 2026 in San Antonio
- Strategic reference site role providing first-mover access to NMR-based diagnostics
- Pre-institutional pricing secured ahead of LarmorBio's planned Series A financing
- Co-dependent strategic partnership model aligning commercialization and validation efforts
Negative
- None.
News Market Reaction – VBIO
In the May 15 session, VBIO declined 5.47%, reflecting a notable negative market reaction. Argus tracked a peak move of +10.4% during that session. Argus tracked a trough of -16.5% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 11 | Earnings date notice | Neutral | +15.6% | Announcement of Q1 2026 earnings release and related conference call. |
| May 06 | Facility opening | Positive | +2.0% | Opening of Velocity Bioworks biomanufacturing facility for Entolimod production. |
| May 05 | Clinical funding support | Positive | -3.4% | NIAID protocol with up to $7 million in BLA-enabling in vivo funding. |
| May 04 | Executive appointment | Positive | -3.4% | Appointment of new General Counsel to support legal and regulatory strategy. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has produced mixed reactions: operational and funding positives sometimes saw negative price moves, indicating inconsistent alignment between news tone and price.
Over recent weeks, Valion Bio announced several developments: a Q1 2026 earnings date on May 14, 2026, the grand opening of its Velocity Bioworks biomanufacturing facility in San Antonio on May 6, 2026, NIAID’s FDA‑precedent protocol enabling up to $7 million in fully funded in vivo studies for Entolimod on May 5, 2026, and the appointment of a new General Counsel on May 4, 2026. Today’s diagnostics-focused licensing news extends this operational build-out around Velocity Bioworks and Entolimod.
Key Terms
nuclear magnetic resonance medical
cdmo technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
First Commercial Installation Targeted for July 2026 in
Valion Bio secured the exclusive license and reference site arrangement at pre-institutional pricing, ahead of LarmorBio's pending Series A financing. The structure aligns the two companies as co-dependent strategic partners — rather than in a conventional vendor-customer relationship — with both parties commercially and operationally aligned on the validation, optimization, and scaled deployment of the BioScan-NMR platform.
"Securing exclusive commercial rights to BioScan-NMR ahead of LarmorBio's Series A reflects how we are building Velocity Bioworks — early access to differentiated technologies, structural alignment with the developer, and a position that strengthens as the platform scales," said Michael K. Handley, Chief Executive Officer of Valion Bio. "Hosting the first commercial installation gives Velocity Bioworks a defined role in the validation and commercialization of a next-generation NMR platform, and supports an advanced diagnostics service offering that we believe will benefit the biomanufacturing of programs both our internal pipeline and our third-party CDMO clients."
The
About Valion Bio, Inc.
Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO) is a clinical-stage immunotherapeutics company developing Entolimod, a TLR5 agonist, for Acute Radiation Syndrome (ARS), oncology supportive care, and longevity indications. Entolimod for ARS has received Fast Track and Orphan Drug designations from the
About Velocity Bioworks
Velocity Bioworks, a wholly owned subsidiary of Valion Bio, Inc., is a full-service contract development and manufacturing organization (CDMO) headquartered in San Antonio,Texas. Velocity Bioworks provides biomanufacturing, process development, and advanced analytics services to biotechnology and biopharmaceutical clients, while also serving as the manufacturing engine for Valion Bio's internal drug development pipeline.
About LarmorBio, Inc.
LarmorBio, Inc. is a life sciences and clinical diagnostics company developing the BioScan-NMR™ platform, a next-generation microscale nuclear magnetic resonance (NMR) system for rapid, label-free phenotyping of live cells and micro-sized biological samples. Founded as a Massachusetts Institute of Technology (MIT) spin-off, LarmorBio's technology is designed to deliver molecular-level diagnostic information from small sample volumes in minutes, without the cryogenics, dedicated infrastructure, or specialized personnel required by conventional NMR instrumentation. The Company's platform supports applications across bioprocessing, cell and gene therapy development, and clinical diagnostics. For more information, visit www.larmorbio.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Valion Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict.
Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of the company's interactions with and guidance from the FDA and other regulatory authorities; the continued interest of BARDA and other
Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Valion Bio's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, under the heading "Risk Factors", as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and the company undertakes no duty to update such information except as required by applicable law.
Investor + Media Contact:
Rich Cockrell
CG Capital
vbio@cg.capital
View original content to download multimedia:https://www.prnewswire.com/news-releases/valion-bios-velocity-bioworks-secures-exclusive-commercial-license-to-larmorbios-bioscan-nmr-platform-302772886.html
SOURCE Valion Bio, Inc.